United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. trimmed its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.4% in the 1st quarter, HoldingsChannel reports. The firm owned 16,725 shares of the biotechnology company’s stock after selling 246 shares during the period. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $5,156,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Dunhill Financial LLC grew its stake in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC acquired a new position in United Therapeutics during the 1st quarter worth $49,000. State of Wyoming acquired a new position in United Therapeutics during the 4th quarter worth $62,000. Curat Global LLC acquired a new position in United Therapeutics during the 1st quarter worth $63,000. Finally, Millstone Evans Group LLC acquired a new position in United Therapeutics during the 4th quarter worth $67,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

United Therapeutics stock opened at $286.88 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The company has a market capitalization of $12.94 billion, a P/E ratio of 11.45, a PEG ratio of 6.32 and a beta of 0.57. The stock has a 50-day simple moving average of $300.56 and a 200-day simple moving average of $329.33.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $6.17 EPS. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. Bank of America lowered their price objective on United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research report on Wednesday, June 11th. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. Cantor Fitzgerald initiated coverage on United Therapeutics in a research report on Monday, June 2nd. They set an “overweight” rating and a $405.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Finally, Wall Street Zen cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $10,297,208.76. This represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer now directly owns 8,118 shares of the company’s stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $23,907,950 in the last ninety days. Insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.